menu
    • menu
    [{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Quetiapine Hemifumarate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"OWP Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"OWP Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OWP Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla Medpro","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ Cipla Medpro","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Cipla Medpro"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Moksha8","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ Moksha8","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Moksha8"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Alvogen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ Alvogen","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Alvogen"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"CAP ALTER PHARMA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ CAP ALTER PHARMA","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ CAP ALTER PHARMA"},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"OWP Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Liquid Oral Suspension","sponsorNew":"OWP Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OWP Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distriphil","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ Distriphil","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Distriphil"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Luye Pharma \/ Zuellig Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Zuellig Pharma"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distribution Solutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Luye Pharma \/ Distribution Solutions","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Distribution Solutions"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Luye Pharma \/ Cipla","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Cipla"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"ICI Pakistan Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Luye Pharma \/ ICI Pakistan Limited","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ ICI Pakistan Limited"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"DCH Auriga","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Luye Pharma \/ DCH Auriga","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ DCH Auriga"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Quetiapine Hemifumarate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem Laboratories Limited \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Quetiapine Hemifumarate

    Menu

    Quetiapine Hemifumarate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Approved

    Sponsor : DCH Auriga

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Luye Pharma and DCH Auriga Establish an Exclusive Distribution Partnership and Jointly Launch the "We Care Abo...

    Details : Luye Pharma grants Auriga exclusive distribution and marketing rights for Seroquel® (quetiapine fumarate, immediate release formulation) and Seroquel XR® (extended release formulation) in Singapore.

    Product Name : Seroquel

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    December 13, 2022

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Sponsor : DCH Auriga

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Approved

    Sponsor : ICI Pakistan Limited

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Luye Pharma Enters Local Seroquel® Distribution and Marketing Partnership with ICI Pakistan Limited

    Details : Luye grants ICI Pakistan exclusive rights to distribute Seroquel (quetiapine fumarate, immediate release) and Seroquel XR (extended release formulation), atypical anti-psychotic medicines with antidepressant properties, for schizophrenia & bipolar disord...

    Product Name : Seroquel

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    September 26, 2022

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Sponsor : ICI Pakistan Limited

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Unichem Laboratories Limited

    India arrow
    BePharma
    Not Confirmed

    Unichem Laboratories Limited

    India arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Unichem Gets ANDA Approval for Generic Quetiapine

    Details : Quetiapine fumarate Extended-Release Tablets acts as dopamine type 2 (D2) and serotonin type 2A (5HT2A) antagonism, which is indicated for the treatment of Schizophrenia and Bipolar I disorder.

    Product Name : Seroquel XR

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    August 17, 2022

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Approved

    Sponsor : Zuellig Pharma

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Luye Pharma Enters Distribution Agreement with Zuellig Pharma for Seroquel and Seroquel XR in Malaysia and Bru...

    Details : Luye grants Zuellig exclusive rights to distribute Seroquel (quetiapine fumarate, immediate release) and Seroquel XR (extended release formulation), atypical anti-psychotic medicines with antidepressant properties, for schizophrenia & bipolar disorder, i...

    Product Name : Seroquel

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    August 02, 2021

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Sponsor : Zuellig Pharma

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Approved

    Sponsor : Distriphil

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Luye Pharma and Distriphil Enter Exclusive Distribution Partnership in the Philippines

    Details : Luye Pharma grants Distriphil the exclusive distribution and marketing rights for the central nervous system drugs Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in the Philippines.

    Product Name : Seroquel

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    November 26, 2020

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Sponsor : Distriphil

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Approved

    Sponsor : Distribution Solutions

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Luye Pharma and Distriphil Enter Exclusive Distribution Partnership in the Philippines with Joint Commitment t...

    Details : Luye grants Distriphil exclusive rights to distribute Seroquel (quetiapine fumarate, immediate release) and Seroquel XR (extended release formulation), atypical anti-psychotic medicines with antidepressant properties, for schizophrenia & bipolar disorder...

    Product Name : Seroquel

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    November 26, 2020

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Sponsor : Distribution Solutions

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    OWP Pharmaceuticals

    U.S.A arrow
    BePharma
    Not Confirmed

    OWP Pharmaceuticals

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : IND Enabling

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    OWP Pharmaceuticals Gets IND Approval for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fuma...

    Details : The potential advantage of this alternative dosage form of Quetiapine Fumarate is that it may be preferred for adult patients who experience swallowing difficulties or for adults and adolescents who have trouble swallowing tablets.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    October 07, 2020

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : IND Enabling

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Approved

    Sponsor : CAP ALTER PHARMA

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Luye Pharma Signs Two Agreements in Latin America, Global Business System for Seroquel Continues to Grow Rapid...

    Details : Luye Pharma granted exclusive promotional rights to CAP ALTER PHARMA, INC (Alter-Pharma) for Seroquel products in 9 countries and regions including Costa Rica, Jamaica, Trinidad and Tobago, Barbados, Aruba, Curacao, Bahamas, Bermuda and The Cayman Island...

    Product Name : Seroquel

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    September 11, 2020

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Sponsor : CAP ALTER PHARMA

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Approved

    Sponsor : Alvogen

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Luye Pharma Enters Distribution and Marketing Partnerships in South Korea, Hong Kong, and Thailand for Seroque...

    Details : Luye Pharma granted Alvogen Korea, Zuellig Pharma and DKSH exclusive distribution and marketing rights to Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in their respective regions of South Korea, Hon...

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    June 01, 2020

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Sponsor : Alvogen

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed

    Luye Pharma

    China arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Approved

    Sponsor : Moksha8

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Luye Pharma Grants Exclusive Promotion Rights to Moksha8, Deepening Strategic Presence in Latin America for CN...

    Details : Moksha8 subsideries, Moksha8 Brasil Distribuidora e Representação de Medicamentos Ltda and Moksha8 Farmacéutica, S. de R.L. de C.V have been granted the exclusive promotion rights for the two central nervous system (CNS) drugs: Seroquel® and Seroquel...

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    May 14, 2020

    Lead Product(s) : Quetiapine Hemifumarate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Sponsor : Moksha8

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth